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Surgeons recommend dissecting lymph nodes in the thorax, abdomen, and neck during 
surgery for esophageal cancer because of the possibility of metastasis to the lymph nodes 
in those areas through the lymphatic plexus of the esophageal submucosal layer. Exten-
sive lymph node dissection is essential for accurate staging and is thought to improve sur-
vival. However, it can result in several complications, including chyle leakage, which refers 
to continuous lymphatic fluid leakage and can occur in the thorax, abdomen, and neck. 
Malnutrition, fluid imbalance, and immune compromise may result from chyle leakage, 
which can be potentially life-threatening if it persists. Therefore, various treatment meth-
ods, including conservative treatment, pharmacological treatment such as octreotide in-
fusion, and interventions such as thoracic duct embolization and surgical thoracic duct li-
gation, have been applied. In this article, the risk factors, diagnosis, and treatment methods 
of chyle leakage after esophagectomy are reviewed.
Keywords: Chyle leakage, Esophageal neoplasms, Esophagectomy, Chylothorax, Chylo-
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Introduction
Esophageal surgery is an invasive procedure used to treat 
esophageal cancer. This procedure involves esophagecto-
my; extensive lymph node dissection at the thorax, abdo-
men, and neck; and reconstruction of the gastrointestinal 
tract. The morbidity rate after esophagectomy has been re-
ported to be 50% based on a large-scale database [1,2]. 
Chyle leakage is a relatively rare complication, but it can be 
potentially life-threatening. If left untreated, it may result 
in hyponatremia, hypoproteinemia, edema, and malnutri-
tion with decreased immune function, which may contrib-
ute to sepsis and increased mortality [3]. Therefore, the 
immediate diagnosis and treatment of chyle leakage after 
esophagectomy are very important. In this article, we re-
view the diagnosis, risk factors, and treatment of chyle 
leakage after esophagectomy.
Anatomy of the thoracic duct
The thoracic duct is the primary structure that returns 
chyle from both sides of the body below the diaphragm to 
the venous circulation. It is approximately 36–45 cm long 
and 2–3 mm wide. It originates from the cisterna chyli in 
the abdomen, which is formed by the confluence of the 2 
lumbar lymphatic trunks and the intestinal trunk. It enters 
the chest through the aortic hiatus between the azygos vein 
and the aorta in the right chest, crosses to the left chest at 
the level of the fifth thoracic vertebra, and enters the left 
jugulo-subclavian venous junction (Fig. 1). The lymphatic 
flow of the abdomen, left side of the face, hemithorax, and 
upper extremity runs into the left jugulo-subclavian ve-
nous junction, whereas that from the right side of the face, 
hemithorax, and upper extremity runs into the right jugu-
lo-subclavian venous junction. The thoracic duct route is 
estimated to be typical in 40%–60% of all cases, while the 
other 40%–60% of patients have anatomic variations of the 
thoracic duct [4] (Fig. 2A). In addition, there are so many 
anatomical variations at the thoracic duct course and 
around the bilateral subclavian vein (Fig. 2B, C) that injury 
and subsequent leakage of unrecognized thoracic duct trib-
utaries during transthoracic esophagectomy may put the 
patient at an increased risk of postoperative chyle leakage 
[5]. This is one reason why surgeons sometimes damage 
the thoracic duct during surgery despite vigilance. The 
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directional f low of chyle, and normal respiration helps 
pump the chyle toward the venous circulation. Similar to 
the medium or large-sized vessels, the thoracic duct has a 
smooth, contractile muscle layer.
Physiology of chyle
Approximately 2.4 L of chyle is transported through the 
lymphatic system every day. The primary role of the tho-
racic duct is to carry 60%–70% of ingested fat at a concen-
tration of 0.4–6 g/dL from the intestine to the circulatory 
system [6]. Chyle is composed of lymphatic fluid and chy-
lomicrons from the gastrointestinal system. Its lymphatic 
f luid contains protein, white blood cells, electrolytes, 
fat-soluble vitamins, trace elements, and glucose absorbed 
from the interstitial f luid to be returned to the systemic 
circulation [7]. Lymph is the other main constituent of 
chyle and is made up of immunoglobulins, enzymes, diges-
tive products, and 400–6,800 white blood cells/mL, the 
majority of which are lymphocytes. Chylomicrons consist 
Fig. 1. Anatomy of the thoracic duct. 
The right lymphatic duct returns 
lymph from the right body above 
the diaphragm. The thoracic duct 
returns lymph from the entire left 
and right sides of the body below 
the diaphragm. The thoracic duct 
originates from the cisterna chyli, 
which is a dilated sac at the level 
of the second lumbar vertebra. The 
thoracic duct crosses from right to 
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Fig. 2. Variations in the course of 
lymphatic drainage. (A) Thoracic 
duct. (B) Right subclavian vein area. 
(C) Left subclavian vein area.
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of esterified monoglycerides and fatty acids combined with 
cholesterol and proteins. These are formed from the break-
down products of long-chain fatty acids by bile salts and 
absorbed into the lymphatic system through special lym-
phatic vessels in the villous region of the intestines, known 
as lacteals. Conversely, the smaller short- and medi-
um-chain fatty acids are more water-soluble and are ab-
sorbed via the intestinal mucosa directly into the hepatic 
portal vein, bypassing the lymphatic system. To prevent 
retrograde f low, chyle is propagated within the thoracic 
duct primarily by the muscular action of breathing and 
further facilitated by the duct’s smooth muscles and inter-
nal valves. Factors that modulate chyle f low include diet, 
intestinal function, physical activity, respiration rate, and 
changes in the intra-abdominal and intra-thoracic pressure 
[8].
Diagnosis of chyle leakage
In patients experiencing chyle leakage, the fluid that is 
drain ed from the chest tube or Hemovac is often milky in 
appearance. The drain fluid color and characteristics are 
unique, but the diagnosis must be made based on laborato-
ry findings and not by visual inspection. Another cause of 
milky-appearing drainage is pseudochyle, also known as 
cholesterol and chyliform effusions, which are cholester-
ol-rich fluids associated with chronic inflammatory disor-
ders [9,10]. Pseudochyle is clinically defined as the combi-
nation of a milky pleural effusion, a pleural cholesterol 
level greater than 200 mg/dL, a pleural triglyceride level 
typically below 110 mg/dL, a pleural cholesterol/triglycer-
ide ratio of greater than 1, and often the presence of cho-
lesterol crystals on microscopy [9,11,12]. The following di-
agnostic criteria must be met for chyle leakage to be 
diagnosed: triglycerides >110 mg/dL, cholesterol <200 mg/
dL, and presence of chylomicrons. However, the above cri-
teria may not be met when the patient is fasting, and the 
drainage color can be serous with a normal level of tri-
glycerides. If the drainage volume from the chest tube or 
other tubes is large and does not diminish over time, chyle 
should be suspected first after esophagectomy, and an ac-
curate diagnosis should be made after the initiation of oral 
intake.
Chylothorax
Chylothorax is a relatively uncommon, but well-known 
complication after esophagectomy. Despite improvements 
in operative strategies for esophageal cancer, the incidence 
of chylothorax is approximately 1.1%–21% in patients who 
undergo esophagectomy [13,14]. Chylothorax occurred in 7 
(1.3%) of 536 patients who underwent esophagectomy for 
esophageal cancer between July 2006 and June 2019 at Sev-
erance Hospital. Of the patients with chylothorax, 3 were 
treated with surgical thoracic duct ligation, 2 with emboli-
zation, and 2 with conservative treatment.
Risk factors for chylothorax
The risk factors for chylothorax have been reported in 
many studies. Usually, extensive lymph node dissection 
and sometimes en bloc resection of the thoracic ducts are 
recommended in esophageal cancer surgery for oncologic 
reasons. With the increase of surgical extent, the risk of in-
juries in the main thoracic duct or thoracic tributaries is 
increased. Usually, the thoracic duct is more prone to dam-
age if a patient has a higher clinical TNM (tumor-node- 
metastasis) stage because the tumor borders the thoracic 
duct more closely at a higher clinical stage [15]. The impact 
of neoadjuvant therapy for the treatment of esophageal 
cancer on postoperative chylothorax incidence is unknown 
and controversial. Gupta et al. [16] evaluated 45 patients 
with esophageal cancer who underwent esophagectomy af-
ter neoadjuvant chemoradiotherapy and reported that dif-
ficult mediastinal dissection during esophagectomy in 
middle esophageal cancer may result in thoracic duct inju-
ries, and a complete response to neoadjuvant chemoradia-
tion may reduce the risk of chylothorax. Gronnier et al. [17] 
outlined the results from a European multicenter study 
and suggested that neoadjuvant chemoradiotherapy in-
creased chylothorax rates, with a trend toward more car-
diovascular and thromboembolic events. Preoperative ra-
diation to the mediast inum may damage the loca l 
lymphatic system and consequently delay the healing of 
small lymphatic vessel stumps caused by lymphadenecto-
my in the affected region, thereby causing chylothorax. In 
some cases, the primary tumor and a tumor embolus di-
rectly invade and erode the thoracic duct, and when the 
pressure of the tumor distends the thoracic duct tributar-
ies, the weak spots can rupture [18]. It may be argued that 
chemoradiotherapy increases the incidence of postopera-
tive chylothorax.
Other risk factors may cause chylothorax. Miao et al. [19] 
found that the incidence of chylothorax was 2.6% in 1,290 
patients who underwent esophagectomy, and those with a 
body mass index (BMI) <25 kg/m2 were more likely to de-
velop chylothorax. Weijs et al. [14] reported that the inde-





were the transthoracic approach, neoadjuvant chemoradio-
therapy, and preoperative BMI. Ohkura et al. [20] found 
that balanced or negative intraoperative fluid balance re-
duced the incidence of postoperative chylothorax. They re-
duced the intraoperative f luid balance to meet the target 
value, which was less than 6.55 mL/kg/hr, and found that 
fluid management at a lower rate may be beneficial in pre-
venting chylothorax. Moreover, they explained that excess 
perioperative fluid accumulation resulted in elevated inter-
stitial f luid volume, and the consequent increase in the 
pressure inside the lymphatic vessels and thoracic duct 
made them leak-prone.
Some authors advocate routine intraoperative thoracic 
duct ligation to prevent chylothorax. Lin et al. [21] ana-
lyzed 296 patients who underwent esophagectomy, and the 
patients who underwent thoracic duct ligation showed low-
er chylothorax incidence (9.1% versus 0%, p<0.01). Howev-
er, Lei et al. [22] disclosed the results of a meta-analysis on 
the effect of prophylactic thoracic duct ligation. In their re-
port, no significant difference was found in postoperative 
chylothorax incidence between the patients who did and 
did not undergo prophylactic duct ligation [22]. Occasion-
ally, irrespective of whether the thoracic duct is preserved 
or resected in esophagectomy, chylothorax still occurs even 
when the thoracic duct is ligated or clipped. One reason for 
this is the looseness of the ligation or slippage of the clips, 
and other reasons include anatomical variations and un-
identified abdominal or thoracic tributaries of the thoracic 
duct that are injured during the operation.
Conservative treatment
There is no standard therapeutic strategy for chylothorax 
because of the lack of prospective randomized trials evalu-
ating the available treatment options, which mainly depend 
on physicians’ and surgeons’ experience [15]. The proposed 
treatment methods for chyle leakage are summarized in 
Table 1. Initial chylothorax treatment is usually conserva-
tive. The cornerstone of treatment is adequate f luid and 
electrolyte replacement, along with appropriate nutrition 
(with total parenteral nutrition [TPN] or medium-chain 
triglyceride [MCT] diet), drainage of the effusion, and pro-
phylactic antibiotics. Due to the potential of high-volume 
fluid shift with protein and electrolyte loss caused by chyle 
leakage, patients with chylothorax need to be monitored 
for dehydration and malnutrition. Nutritional status, fluid, 
and electrolyte balance should be checked to avoid nutri-
tional deficiency or further complications. Intravenous flu-
ids including TPN should be administered to achieve eu-
volemia and electrolytes should be replenished as needed. 
Dietary management plays a crucial role in conservative 
chylothorax treatment. During the period of chyle leakage, 
the authors usually use the MCT diet at first, followed by 
TPN if the drainage does not decrease [23]. Nevertheless, 
others recommend using TPN initially. Benedix et al. [24] 
reported that triglyceride and chylomicron levels in drain-
age fluid can rise on an MCT diet and water-only diet and 
increase output drainage by 20% in some patients. Even 
with an MCT diet, if a patient shows high chyle output, 
strict fasting with TPN that completely bypasses the lym-
phatic system is usually recommended. The use of TPN 
must be carefully weighed against its need for central ve-
nous access, the potential complications of infection and 
venous thrombosis, metabolic disturbances, and its high 
cost [25]. Patients are generally advised to consume a low-
fat and MCT diet [26]. In general, an MCT diet with pro-







Chylothorax Fluid replacement; IV nutrition; diet 
(MCT diet or NPO); clamping the 
drainage tube at the abdomen or 











Chyloperitoneum Fluid replacement; IV nutrition; diet 
(MCT diet or NPO); clamping the 
drainage tube at the abdomen or 





OK-432 injection; radiation at 
the cisterna chyli; Denver shunt 




Chyle leakage  
at the neck
Fluid replacement; IV nutrition; diet 
(MCT diet or NPO); clamping the 
drainage tube at the abdomen or 










IV, intravenous; MCT, medium-chain triglycerides; NPO, nil per os; OK-432, Picibanil.
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tein, metabolic mineral mixture, and multivitamin supple-
mentation is preferable to a nonfat diet. Because the MCT 
diet is largely water-soluble and absorbed via the portal ve-
nous circulation rather than the gastrointestinal lymphat-
ics, this special diet bypasses the gastrointestinal lymphatic 
system, reducing chyle leakage and allowing the thoracic 
duct injury to heal faster [27]. If the MCT diet cannot be 
taken orally, MCT powder can be administered through 
jejunostomy or Levin tubes.
Pharmacologic treatment
In addition to conservative treatment, several pharmaco-
logic agents can be considered simultaneously. Somatosta-
tin is a neuroendocrine hormone discovered in 1973, with 
numerous effects on the digestive and lymphatic systems 
[28]. Two possible mechanisms through which somatosta-
tin ameliorates chyle leakage have been suggested. Soma-
tostatin decreases chyle production via the reduction of 
gastric, pancreatic, and intestinal secretions [29]. It also 
constricts smooth muscles in the splanchnic and lymphatic 
vessels to decrease lymph production [23] and lymph flow 
[30], respectively. A major drawback of somatostatin is its 
short half-life, which requires continuous intravenous in-
fusion. This problem was solved with the development of 
octreotide, a long-acting analog of somatostatin, which can 
be administered through long-lasting subcutaneous injec-
tions [31]. To date, there are no consensus guidelines on 
the optimal octreotide treatment dose and duration in chy-
lothorax management. In previous papers, octreotide dos-
age ranged from 100 μg (subcutaneous) every 8 to 12 hours 
to 200 μg (subcutaneous) every 8 hours [32]. Furthermore, 
some clinicians have infused octreotide continuously. The 
time from octreotide therapy initiation to chyle leakage 
cessation ranged from 1–15 days, and the total octreotide 
treatment duration varied widely from 3–24 days. In gen-
eral, octreotide is administered for an additional 1–2 days 
after chyle leakage cessation to ensure complete resolution. 
The most common side effects of octreotide are nausea, 
abdominal discomfort, and diarrhea. Rare but serious 
complications include hypoglycemia and cholecystitis sec-
ondary to cholestasis. In fewer than 1% of patients, ana-
phylactic shock, gastrointestinal bleeding, and pulmonary 
embolism have been described. Octreotide should be pre-
scribed with caution in patients with preexisting cardio-
vascular and hepatic diseases [31]. Most adverse effects are 
dose- and duration-dependent.
Etilefrine is a sympathomimetic drug used in postural 
hypotension [33]. It causes smooth muscle fiber contrac-
tion in the thoracic duct, similar to somatostatin [34], re-
sulting in the reduction of the amount of chyle and repair 
of the injury sites. Etilefrine has a few side effects including 
headache, tachycardia, anxiety, and flushes [35]. Unfortu-
nately, etilefrine is not currently available in South Korea. 
Orlistat, a pancreatic lipase inhibitor, interferes with lipid 
metabolism in the duodenum and prevents lipid absorp-
tion and may be given as an adjunct to decrease chyle pro-
duction [36], but it is not available in South Korea. Pleu-
rodesis with chemical agents such as talc can be performed 
in addition to conservative and pharmacologic treatments.
Interventions: thoracic duct ligation and 
embolization
Most patients with chyle leakage recover after conserva-
tive treatment. However, the authors consider invasive 
treatments if chylothorax persists. The timing of invasive 
procedures is controversial. Usually, the amount of drain-
age, duration, and the patient’s condition must be taken 
into account. Selle et al. [37] recommended an operation to 
ligate the thoracic duct when chyle leakage persists for at 
least 5 days at the rate of 1,500 mL/day or more in adults 
and when the drainage of chyle does not decrease within 
2 weeks or the patient’s nutritional or metabolic status be-
comes measurably more impaired during the same period. 
The authors also have experienced secondary infections in 
patients with chylothorax related to immune compromise, 
which can be an important criterion for deciding upon an 
invasive procedure [38].
Surgical ligation of the thoracic duct is a classical meth-
od to treat chylothorax. The thoracic duct is found between 
the descending thoracic aorta and azygos vein. Fatty fluid 
infusion via a Levin tube, before or during the operation, 
aids in finding the leakage point. If the leakage point is 
noted, the proximal area of the thoracic duct can be ligated 
with a suture or clip. Ligation at the diaphragm level is 
generally recommended. This procedure usually can be 
done through a right-side approach. Because most previous 
reports on surgical ligation of the thoracic duct were case 
series, the exact success rate is difficult to quantify, but 
chylothorax can usually be treated if ligation is properly 
executed [39].
Recently, thoracic duct embolization has replaced surgi-
cal thoracic duct ligation for the treatment of chylothorax. 
Thoracic duct lymphangiography can be done by inguinal 
lymphangiography. Under direct ultrasound guidance, 
physicians identify and assess superficial inguinal lymph 





until contrast is seen coursing cranially and opacifying the 
cisterna chyli or the thoracic duct. If extravasation of con-
trast material is identified, embolization of the thoracic 
duct with a liquid embolic agent (Lipiodol) and/or coils is 
performed across or proximal to the leak point [40]. The 
success rate of thoracic duct embolization depends on the 
institutional experience and has been reported to be 45%–
78% [41]. Lower extremity edema and chronic diarrhea are 
the most frequent significant complications that arise from 
thoracic duct embolization [42]. Because thoracic duct em-
bolization does not require general anesthesia, it can be 
performed more easily than surgical thoracic duct ligation. 
After introducing thoracic duct embolization at our insti-
tution, we make quick decisions to perform embolization 
without long periods of observation.
Chyloperitoneum
Chyloperitoneum is defined as a milky-appearing, tri-
glyceride-rich peritoneal f luid characterized by the pres-
ence of thoracic or intestinal lymph in the abdominal cavi-
ty [43]. Studies have determined various etiologies of 
chyloperitoneum, such as abdominal malignancy; liver cir-
rhosis, infection, or inflammation; or trauma, including 
abdominal lymph node dissection. In cases of esophagec-
tomy, abdominal lymph node dissection might be related 
to chyloperitoneum. Of particular note, the celiac axis and 
common hepatic lymph node dissection during esophagec-
tomy is related to chyloperitoneum. The authors always 
check the dissected area of the celiac axis and common he-
patic lymph nodes at the end of the operation, and if the 
leakage is suspected, these areas are sealed and closed with 
non-absorbable sutures. The exact incidence of chyloperi-
toneum have not been reported due to its rarity. At Sever-
ance Hospital, its incidence is only 0.56% (4 cases) from 
July 2006 to June 2019. Three of these cases were treated 
with conservative treatment, and an OK-432 injection was 
administered in 1 case.
Treatment of chyloperitoneum
The treatment of chyloperitoneum is similar to that of 
chylothorax, especially regarding conservative and phar-
macologic treatments. The abdominal cavity pressure is al-
ways positive, whereas the intrathoracic pressure is always 
negative. Clamping of the drainage tube could be effective, 
unless the patient shows abdominal discomfort, dyspnea, 
or secondary pleural effusion. Sometimes, the increased 
abdominal pressure might obliterate the chyle leakage in 
the abdomen. Patients with clinical symptoms due to chy-
loperitoneum require repeated paracentesis or drainage to 
decrease the discomfort related to the increased intra-ab-
dominal pressure and the concomitant respiratory insuffi-
ciency caused by the large abdominal fluid collection, the 
impaired venous return, and the displaced diaphragm.
Additional treatment options could be applied. A scle-
rosing agent can be injected into the suspicious leakage 
point. Inaba et al. [44] reported the local intraperitoneal 
administration of OK-432 (Picibanil) using a unified com-
puted tomography and f luoroscopy system for the treat-
ment of chyloperitoneum after gastrectomy, and this tech-
nique can be applied after esophagectomy. The authors 
also applied this procedure successfully in the case of chy-
loperitoneum after esophagectomy and abdominal lymph 
node dissection. Some previous case reports have stated 
that low-dose radiation therapy at the cisterna chyli can re-
lieve chyloperitoneum [45]. Brown et al. [45] reported a pa-
tient who was treated with a dose of 10 Gy in daily 1-Gy 
fractions to the para-aortic region, including the cisterna 
chyli and thoracic duct from T12 to L2. Low-dose ionizing 
radiation exhibits anti-inflammatory and apoptotic effects 
that cause fibrosis or scarring of tissue after trauma, and 
low-dose radiation can therefore obliterate the chyle leak-
age point. A peritoneo-jugular shunt (Denver or LeVeen 
shunt) can also be a good treatment option for chyloperito-
neum. Chyle is aseptic in nature and can be drained into 
the systemic venous circulation by the peritoneo-jugular 
shunt. However, these shunts are not commercially avail-
able in South Korea [46]. A transjugular intrahepatic por-
tosystemic stent shunt creates a communication between 
the portal and systemic circulation within the liver. By re-
ducing portal pressure, it can relieve lymphatic hyperten-
sion [47].
Surgical ligation of the leakage point in cases of chylo-
peritoneum is technically challenging. It must be considered 
the last treatment modality because of its high probability 
of failure. Preoperative lymphangiography or lymphoscin-
tigraphy is helpful in identifying the anatomical location of 
the leakage or the presence of a fistula. Matsutani et al. [48] 
reported a case in which the transabdominal approach was 
successfully used for chyloperitoneum after esophagectomy 
by using fluorescence navigation with indocyanine green. 
They injected indocyanine green in the inguinal lymph 
nodes, as in thoracic duct lymphangiography, and they 
documented the chyle leakage points under a fluoroscopic 
camera. Even though these novel techniques can be help-
ful, an exploratory laparotomy should be performed as a 
last resort. In addition, cisternal chyli embolization for 
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chyloperitoneum is not usually performed [41].
Chyle leakage at the neck
Because the exact incidence of chyle leakage after esoph-
agectomy has not been reported, we can infer its incidence 
from the results of head and neck surgery as 0.5%–1.4% of 
thyroidectomies [49,50] and 2%–8% of neck dissections 
[51,52]. If the surgeons perform 3-field lymph node dissec-
tion, chyle leakage at the neck theoretically occurs in 2%–
8% of cases, but the real chyle leakage incidence after 
esophagectomy might be lower than that assumption. If 
the amount of neck drainage increases, especially after en-
teral feeding, and if erythema, lymphedema, or palpable 
f luid collection is observed in the supraclavicular area, 
chyle leakage can be strongly suspected [27]. Usually, the 
drainage color is creamy or milky; however, the drainage 
can be serous if the thoracic duct is ligated. In addition, 
chyle leakage of the right side of the neck can be serous 
even if the patient consumes a normal meal.
Treatment of chyle leakage at the neck
Conservative treatment is similar to the chylothorax and 
chyloperitoneum. Especially in the neck, clamping of the 
drainage tube can be effective, but lymphocele can form at 
the leakage point. In addition to conservative treatment, 
sclerosing agents such as OK-432 or tetracycline adminis-
tered at the time of surgery or postoperatively through a 
drainage tube or percutaneous injection can generate fi-
brosis to seal chyle leakage at the neck [53]. Sclerotherapy 
should be used with care, as it can potentially injure the 
surrounding structures in the wound bed. Phrenic nerve 
paralysis after doxycycline sclerotherapy for chyle leakage 
has been reported [54]. Furthermore, the authors have ex-
perienced Horner syndrome after OK-432 injection into 
the neck. Transcervical lymphangiography also can be 
done either by a direct approach to the lymphocele or a 
retrograde approach from the cephalic vein [41]. Addition-
ally, Kadota et al. [55] described the successful use of nega-
tive pressure wound therapy (NPWT) for postoperative 
chyle leakage after neck dissection. NPWT is thought to 
facilitate f luid extraction from the wound bed and sur-
rounding interstitial space, thereby hastening granulation 
tissue formation and minimizing dead space [56]. They 
used a relatively a low pressure (50 mm Hg) to avoid an un-
wanted increase in drainage because of the negative pres-
sure, and the leakage resolved within 6 days. Notably, mas-
sive bleeding occurred when NPWT had been applied 
around major vessels [57]. Kadota et al. [55] avoided this 
complication by using gauze to cover the tip of the tube 
connected to the NPWT device and the soft tissues encom-
passing the major vessels and microsurgical anastomoses. 
NPWT is another treatment option for chyle leakage after 
neck dissection. It is minimally invasive, is less burden-
some to patients, and can be applied in intractable cases 
when other conservative treatments fail [23].
Surgical re-exploration should be considered only after 
conservative treatment has either been exhausted or 
deemed ineffective. Although the recommended criteria 
for re-exploration vary considerably, the general consensus 
is that surgical re-exploration should take place when chyle 
leakage does not respond appropriately to conservative 
management. At the time of re-exploration, local inflam-
mation from extravasated chyle can make thoracic duct 
identification difficult. Trendelenburg positioning and the 
Valsalva maneuver, which raise the intra-thoracic and in-
tra-abdominal pressure, can facilitate the identification of 
the site of chyle leakage. Furthermore, providing the pa-
tient with a fatty diet before surgery can stimulate chyle 
production and aid in the localization of the leakage point. 
As described above, when identified, the leaking point can 
be ligated, covered with a muscle flap, or treated with any 
number of sclerosing agents, adhesive agents, or mesh.
Conclusion
Chyle leakage is uncommon, but it can be a serious com-
plication of esophageal cancer surgery. Chyle leakage can 
result in dehydration, malnutrition, electrolyte disturbanc-
es, and immunosuppression. For the diagnosis, the charac-
teristics and laboratory findings of the fluid are essential. 
Furthermore, it is important to consider the possibility of 
chyle leakage if the amount of drainage is high, even if the 
drainage is serous. Conservative treatments with pharma-
cologic agents are essential. The development of thoracic 
duct embolization has enabled surgeons to decide whether 
to perform an invasive procedure more affirmatively and 
actively, minimizing the potential surgical risk.
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